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Lack of recruitment of qualiﬁed research participants continues to be a signiﬁcant bottleneck in clinical
trials, often resulting in costly time extensions, underpowered results, and in some cases early termi-
nation. Some of the reasons for suboptimal recruitment include laborious consent processes and access
to participants at remote locations. While new electronic consents technologies (eConsent) help over-
come challenges related to readability and consent management, they do not adequately address chal-
lenges related to remote access. To address this, we have developed an innovative solution called
“teleconsent”, which embeds the informed consent process into a telemedicine session. Teleconsent
allows a researcher to remotely video conference with a prospective research participant, display and
interactively guide participants in real-time through a consent form. When ﬁnished, the researcher and
participant can electronically sign the consent form and print or download the signed document for
archiving. This process can eliminate challenges related to travel and management of personnel at
remote sites. Teleconsent has been successfully implemented in several clinical trials. Teleconsent can
improve research recruitment by reducing the barriers related to informed consent, while preserving
human interaction.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clinical trials play a critical role in improving quality and
effectiveness of health care by systematically evaluating safety and
efﬁcacy of new treatments or interventions. Despite their impor-
tance, there are signiﬁcant challenges to obtaining high-quality,
timely, and actionable evidence through clinical research. These
challenges include study length, budget restrictions, ethical and
regulatory requirements, and difﬁculty recruiting and retaining
qualiﬁed participants [1]. Recruitment in particular is a major
bottleneck, with 75% of trials failing to reach recruitment goals and
one-third of those failing to enroll any subjects [2]. Worldwide, 90%
of trials fail to recruit the target number of patients within the
allotted time [2]. It is estimated that of those invited to participate,
21% show up for initial screening, 7% enroll and only 5% complete
the trials [1]. Failure to meet recruitment goals leads to costly time.
Inc. This is an open access article uextensions due to issues like unforeseen labor and advertising
costs, suboptimal or underpowered study results, unpublished re-
sults, and even early termination of the clinical triald costing
research institutions and sponsors a substantial amount of money
every year [3,4]. Most importantly, this failure to recruit ultimately
hinders the translation of knowledge and potentially life-saving
interventions into routine clinical practice [5e7].
While 80% of the general population is receptive to clinical trials
[8], there are several barriers for adequate recruitment, including
lack of physician or patient awareness, socio-demographic pres-
sures, concern over clinical equipoise, and difﬁculties in the
informed consent process [8e11]. Challenges related to the
informed consent process include (1) patient travel burden, (2)
workﬂow challenges, (3) scheduling difﬁculties between the
research staff and participant, and (4) patient's difﬁculty in un-
derstanding the consent document [12,13]. Furthermore, clinical
trials are often conducted in proximity to an investigator, making it
difﬁcult for interested and eligible individuals who live far from the
investigator to participate [2]. The current widely used approach of
obtaining informed consent involves a face-to-face meetingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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However, if a participant is recruited at a remote clinical site, one or
both parties must travel to complete the informed consent process.
This increases travel costs and can be an inefﬁcient use of time.
Alternatively, clinical staff at remote clinics may be trained, how-
ever this (1) requires the staff to complete all necessary regulatory
compliance training, which is not a trivial task; (2) can be disruptive
to the clinical staff's workﬂow, particularly in high volume clinics;
and (3) can lead to incomplete consents or errors, resulting in de-
lays and increased cost in recruitment [14]. Presently, consent can
be obtained remotely using a telephone, mail, fax, or by electronic
means (eConsent), however, these approaches also have their
shortcomings. In summary, the current informed consent process is
a time-consuming process fraught with inefﬁciencies. Available
options to address these challenges and improve informed consent
have had limited impact and utility.
2. The teleconsent solution
To overcome recruitment and consenting challenges, we
developed a telemedicine-inspired product called “teleconsent”,
that allows researchers to obtain informed consent from partici-
pants from anywhere using telemedicine technology. Telemedicine
is a health care delivery model that provides care to patients at a
distance using telecommunications capabilities [15]. It has been
effectively utilized in many clinical domains to reduce costs and
increase access to health care, particularly to rural and underserved
areas [16e22]. Studies have shown that patients are satisﬁed and
often prefer receiving care via telemedicine [23,25]. By utilizing
teleconsent for research recruitment and informed consent, re-
searchers can increase access and improve enrollment in clinical
trials. Additionally, researchers can save time and costs by mini-
mizing travel for participants and study personnel. Teleconsent also
allows researchers to recruit participants outside of their
geographic region, supporting nationwide and even worldwide
recruitment. Teleconsent is not intended to replace existing con-
sent mechanisms, rather, it aims to supplement them in order to
increase access to a wider representation of populations for
research studies.
2.1. Teleconsent features
Teleconsent aims to remotely replicate the capabilities of an in-
person consent process. During an established telemedicine call
between a researcher and participant, the researcher can select and
display an informed consent document that is viewed and
completed with a participant in real-time. As the researcher scrolls
the document, selects text, or completes web form elements (e.g.,
checkboxes, text, date), all actions are updated in real-time on the
participant's screen, and vice versa. The teleconsent document is
coded in HTML5 and therefore supports text, images, audio, video,
and other interactive capabilities. This allows the host to scroll the
document for the participant and highlight a section of the
informed consent that is being discussed, or visually direct the
participant to sections that need to be completed by the partici-
pant. One user can see the other user's cursor position on the
document, which updates in real-time as the cursor moves. Par-
ticipants can also highlight parts of the text they do not understand
for the researcher. The researcher has the ability ﬁll out certain data
ﬁelds for the participant as appropriate. This feature can be
disabled so that only the host or participant has the ability to enter
data in a certain ﬁeld. Together, these features allow teleconsent to
be an interactive and engaging experience, similar to in-person
consent. See Fig. 1.
When the consent document is complete, the host can ‘ﬁnalize’the document. At this point, the program checks to ensure all data
ﬁelds have been ﬁlled out. If required ﬁelds have not been ﬁlled out,
the missing ﬁelds are highlighted in red outline and the document
automatically scrolls to display the ﬁrst missing ﬁeld. When the
document is completely ﬁlled out, a Portable Document Format
(PDF) ﬁle of the completed consent document is generated and
displays to both host and participant's screens. Both users have the
option to print or save the PDF ﬁle; study personnel can save an
electronic copy of the PDF ﬁle directly into their electronic system
of record, such as a clinical trials management system or an elec-
tronic data capture system (e.g., REDCap). The generated document
is only available on the computer of the host and participant.
Included at the end of the PDF ﬁle is an audit trail, which shows the
ﬁeld name, the user who edited it, their role, timestamps and IP
address of the user.
2.2. Template creation and management
Teleconsent documents are created using HTML5 with
embedded javascript code for certain functions. As a result, they
need to be coded by trained web developer with knowledge of the
document syntax. Currently, teleconsent ﬁles can only be uploaded
to the template manager by an enterprise or doxy.me adminis-
trator. Once a consent document is uploaded to the teleconsent
application, it is not possible to change the content of the document
itself (only designated form ﬁelds are editable). This maintains the
integrity of the consent document to ensure that there are no
changes once it has been ﬁnalized and approved by the institu-
tional review board (IRB). Additionally, a hash value is generated for
each document so users can verify that no changes were made to
the document. If changes need to be made to the consent docu-
ment, they must be made outside of the application and uploaded
as a new document, after which the old document can then be
deleted. A teleconsent template manager is available for re-
searchers to view and manage all available teleconsent documents.
Each consent document includes metadata, namely organization
name, study title, principal investigator, IRB number, date approved
by IRB, project status (e.g. pending, approved, in-progress etc),
expiration date, template owner, template author, and template
ﬁnalized (date). Active Templates are consent documents that can be
selected and used during a live teleconsent session, while Inactive
Templates are available for the researcher to preview and/or
manage within the template manager, but they aren't accessible
during a live teleconsent session. Teleconsent manager organizes
inactive templates by access: (1) Personal Templates include docu-
ments that are only available to andmanaged by the researcher; (2)
Enterprise Templates are available to users from the same organi-
zation, and these templates are uploaded and managed only by
enterprise account administrators; and (3) Global Templates are
managed by Doxy.me and available to any teleconsent users.
2.3. Electronic signature
A common challenge with e-documents is the means to obtain a
legally veriﬁable signature that complies with Title 21 CFR Part 11
subpart C, the United States Food and Drug Administration (FDA)
regulations on electronic records and electronic signatures [24].
Simply typing a name in a form ﬁeld is typically not sufﬁcient to
verify identity. Other approaches require users to register for an
account and login to complete the signature, however this option
was too complicated, particularly because Doxy.me platform does
not require the participant to register and login. Therefore, we have
implemented two options for electronic signature. The ﬁrst is a
novel “photo signature” approach for obtaining a veriﬁable signa-
ture from users. The user ﬁrst types his name in a form ﬁeld, the
Fig. 1. A screenshot of a teleconsent session. Users edit and complete the consent document together in real-time. Note that the photo signature has been completed by the
participant. While in a call, the user can edit ﬁelds, select a paragraph by highlighting it and place signature at the same time.
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completed (using the camera feed through Doxy.me), captures the
user's IP address, along with the date and time it was signed.
Together this information provides the legal veriﬁcation
that person signing the document at that place and time is who
they say they are. See Fig. 1. In addition to photo signature option,
the user has the option to free draw their signature using mouse or
ﬁnger on touchscreen devices like mobile devices in an embedded
signature box within the form. Both of these approaches have been
reviewed by legal experts and found to be compliant with Federal
regulation on electronic records and electronic signatures [24].
Photo signature allows the user experience to remain simple (no
registration or logins) while complying with all signature
requirements.2.4. Doxy.me platform
Teleconsent was built as an ‘extension’ to the Doxy.me tele-
medicine platform (https://doxy.me), a free web-based telemedi-
cine solution that utilizes the open-source web real-time
communication (webRTC) technology for peer-to-peer audio-video
telecommunication and data exchange [25]. Doxy.me works
natively within Google Chrome and Mozilla Firefox browsers
without the need for additional plugins or downloads. Mobile apps
are available for download as well. The platform complies with
Health Insurance Portability and Accountability Act (HIPAA) re-
quirements by (1) encrypting all transmitted data, (2) not storing
patient information, (3) keeping an audit trail of sessions, and (4)
signing a business associates agreement (BAA) with the user. A key
feature of Doxy.me is that participants are not required to register,
login, or install additional software or plugins to join a meeting. To
connect, the host simply provides a personalized URL (e.g. https://
doxy.me/DrWelch) to the participant, which the participant uses toenter the host's Doxy.me room.When the participant ﬁrst arrives at
the host's room, Doxy.me checks for system compatibility and as-
sures the camera andmicrophone are enabled. A participant is then
presented with a check-in modal where she provides her name.
When she checks in she enters thewaiting room towait for the host
to start the call. The waiting room can be customized with text,
images, and videos that participants can view while waiting for the
meeting to start. Participants in the waiting room are displayed in a
queue visible to the researcher. The researcher can communicate
with any participant in the queue by text chat to let them know
about their waiting time. When ready, the researcher selects the
participant in the queue to start a session. When the session is
established, the host and the participants can see and hear each
other with options to stop video, mute microphone, expand to full
screen, send and receive a text chat message, and end the call.
Additionally, during the call the researcher has ability to access
additional extensions that add functionality to Doxy.me. Examples
of extensions include three-way calling, photo capture, screen
share, and ﬁle transfer. Doxy.me is currently available in two ver-
sions: the free version and the enterprise version. Both versions
have the ability to use teleconsent. The enterprise edition, allows
organizations to white-label the product to match their own brand
with colors, logos, subdomains, and landing page (e.g., https://
musc.doxy.me). By building upon the Doxy.me telemedicine plat-
form, we were able to quickly develop the teleconsent solution
without concern about the telecommunication aspect.2.5. Privacy and security
Protecting the privacy and conﬁdentiality of users and their data
is an important focus of teleconsent. We took several approaches to
reduce the likelihood of a conﬁdentiality or privacy breach. As
teleconsent is built on the Doxy.me platform, it uses the same peer-
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Therefore, data transmitted between researcher and participants is
protected and secured in the same way as the audio and video. As
teleconsent is a browser-based, peer-to-peer extension, all data
entered into the teleconsent document by the users is not stored on
a server, rather it only exists in the participants' browsers. As a
result, when the user closes the teleconsent document, any data
disappears and is no longer accessible, and the privacy and conﬁ-
dentiality of users are protected. Once the teleconsent document is
ﬁnalized and printed or saved to a user's computer as a PDF ﬁle, it
becomes the responsibility of that user and their organizational
policies to manage and protect the document.2.6. Initial user feedback
Teleconsent has been successfully deployed at large academic
medical centers, rural community hospitals, commercial clinical
research organizations, and small specialty clinics. Researchers,
particularly those who recruit participants from the community
(particularly rural and underserved areas), have been eager to
utilize teleconsent to overcome common barriers and access issues
to the traditional consent approaches. To understand the percep-
tions, barriers, facilitators and motivations regarding teleconsent
usability, we conducted focus groups among research coordinators
at MUSC in the (1) Department of Obstetrics and Gynecology and
(2) South Carolina Translational Research (SCTR) to gain insights
into how teleconsent could beneﬁt their work. These discussions
were approved by IRB. Research coordinators are the ﬁrst line of
people responsible for research recruitment and hence their feed-
back is important. Two focus groups were conducted with a con-
venience sample of 8e10 participants in each focus group and the
durationwas about 60min per focus group. The focus group started
with a short introduction and demonstration of the teleconsent
process in real-time, followed by questions asked by a qualitative
researcher/interviewer. Following oral consent, the conversations
were digitally recorded to assure accuracy. Additionally, notes were
taken by the interviewer as well as a second note taker which
included date and time, comments on the role of the participant(s),
and observations. Field notes and digital recording were tran-
scribed verbatim with strikeouts of any identiﬁers that might
breach subject conﬁdentiality. An iterative process was used to
analyze the data. Transcripts were analyzed by a single reviewer,
followed by review from a secondary reviewer to conﬁrm emergent
interview themes. Systematic comparisons were used for cross-
validation of ﬁndings, negotiating consensus, and ensuring truth-
fulness and rigor of the data analysis process. From this qualitative
approach, initially a few barriers regarding the use of teleconsent
were identiﬁed such as the participant's lack of technical skills,
internet connectivity issues, interpersonal preference for an in-
person meeting, or a busy clinic with lack of access to an avail-
able computer. However, the perceived beneﬁts far outweigh the
barriers. Almost all focus group participants agreed that tele-
consent would be useful and a “time saver” to their work. Other
beneﬁts included remote consenting and re-consenting, mini-
mizing “no shows”, documentation and tracking for research reg-
ulatory purposes (audit trails and photo signature validation). We
have also conducted surveys and interviews with research partic-
ipant teleconsent users to understand participants' (1) ease of using
teleconsent, (2) common problems or challenges, (3) preference
and comfort in using teleconsent. Overall feedback from all the
end-users demonstrates a positive opportunity for using tele-
consent to obtain informed consent in research. A full description of
the methods and results of these surveys will be published in a
subsequent publication.2.7. Internal review board approval
The purpose of IRBs is to ensure that human subjects are pro-
tected in clinical research and informed consent is a critical
component of this process. As teleconsent is a new approach to
obtain informed consent, it is subsequently essential to obtain
approval from IRBs to use teleconsent. In our experience working
with IRBs to gain their approval, we have found that IRBs' primary
concerns include (1) participant information is kept private and
conﬁdential, (2) the integrity of the informed consent document is
intact and veriﬁable, and (3) the IRB can remove or change a tele-
consent template if it is no longer valid. Fortunately, these concerns
are addressable with the current features of teleconsent. IRBs have
also expressed concern that this requires technology (computer
and internet) that may not be easily available to all participants.
While the number of people without access to such technology
with the proliferation of low-cost computers and mobile devices is
declining, it is a valid and important aspect to consider. In such
cases, a proposed solution is for a participant to use a family
member's or friend's computer, or at a public location (e.g., library);
but this solution raises additional concerns about privacy and
conﬁdentiality. Also, IRBs have expressed additional concern about
accessibility for special populations such as adolescents, elderly,
andminorities. The solution used here atMUSC is for the researcher
to conduct several pilot teleconsent sessions with the target pop-
ulation to determine if teleconsent is a feasible strategy, and to
identify potential issues. This strategy has proven successful so far.
It is important for IRBs to understand that teleconsent does not aim
to replace the traditional in-person consent process, but rather to
provide a complementary solution to obtain consent from partici-
pants where the traditional consent approach is not feasible or
practical. In that sense, teleconsent is allowing researchers to
expand the reach and inclusiveness of a research study, something
IRBs are particularly interested in.
3. Discussion
3.1. Advantages of using teleconsent to obtain consent
The current informed consent process is a bottleneck to clinical
trial recruitment, affecting the impact of clinical research. Tele-
consent can overcome gaps and barriers in the traditional informed
consent process by making it possible to consent a research
participant at a distance. By reducing the time and travel required
to obtain consent, teleconsent allows individuals in rural and un-
derserved regions to participate in clinical research. Teleconsent
may be particularly impactful for enhancing participation in trials
by underserved and poor populations who may lack transportation
means but have access to the internet via mobile devices, com-
munity centers, or clinics [26]. Even more, teleconsent allows re-
searchers to recruit participants outside of their geographic region,
supporting nationwide, even worldwide recruitment. For rare dis-
ease research, nationwide recruitment is often a necessity [27].
Teleconsent helps meet this challenge thus facilitating research for
rare diseases. Likewise, multisite clinical trials often struggle with
informed consent bottlenecks related to (1) training and managing
personnel to obtain consent at each remote study site, (2) clinic
workﬂow and resource disruption at remote study sites, (3) the
timely transfer of the completed consent to the researcher, and (4)
incomplete or inappropriately completed consents that need to be
re-done [28e30]. However, teleconsent provides a way to stream-
line and standardize the informed consent process for multisite
clinical trials. By using a centralized hub-and-spoke teleconsent
model, a multisite study can have a single trained individual (or
small group of individuals) at a central location, on demand,
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would just need to access the designated telemedicine room (e.g.,
https://musc.doxy.me/MultisiteStudyX) for the patient for the
consent to take place. This hub-and-spoke teleconsent approach
allows multisite trials to scale more efﬁciently than traditional
consenting approaches because it eliminates multisite consent
challenges related to training clinic staff to obtain a consent prop-
erly and obtaining a complete consent document in a timely
manner.
3.2. Comparison to other remote consent approaches
Teleconsent is not the ﬁrst or only solution that can be used to
obtain consent remotely. Using telephone, mail, or fax to obtain
informed consent has been used, but has its shortcomings. For
example, there is no written documentation or participant signa-
ture when obtaining consent by telephone. Likewise, requiring a
participant to review, sign, and return a consent document by fax or
mail can be logistically challenging and places a signiﬁcant amount
of responsibility on the participant. Moreover, it becomes difﬁcult
to verify the identity of the person signing the document. Obtaining
informed consent remotely using software solutions (i.e., eConsent)
has many advantages to paper-based consent. Researchers can
easily access an electronic library of consent form elements and
templates, incorporate multimedia (i.e., video recordings) into the
consent, and manage completed consent documents [31e33]. Of
note, REDCap and Apple ResearchKit have added features that
support electronic capture of signature and/or informed consent,
expanding the reach of eConsent [34,35]. However, all these remote
consent approaches lack the ability to observe nonverbal cues
indicating that a participant does not understand or feel comfort-
able with certain aspects of the study. Additionally, research has
shown that person-to-person interaction is more effective at
improving informed consent understanding than using multi-
media, tests/feedback, or enhanced forms [36]. Teleconsent, on the
other hand, combines the convenience and accessibility of obtain-
ing consent remotely with the conﬁdence and value of in-person
consent. With teleconsent, the researcher and participant can
view and edit the informed consent document simultaneously, in
real-time with video. This allows the researcher to (1) conveniently
obtain consent at a distance, (2) observe non-verbal cues and
address any ambiguities that the participant has during the consent
process, and (3) support effective person-to-person interaction.
Certainly there are opportunities to incorporate teleconsent fea-
tures with eConsent features to allow researchers to collectively
harness the consent management beneﬁts of eConsent and the
interpersonal beneﬁts from teleconsent.
3.3. Innovative uses of teleconsent
In addition to teleconsent's unique feature to facilitate remote
consent process for researchers, it can also be utilized in innovative
ways to meet speciﬁc research or organizational needs. Some
informed consent situations require or beneﬁt from three in-
dividuals participating in the consent process. For example, some
research studies require the co-signature of a legally authorized
representative (LAR) of a participant, such as a parent, spouse, or
other family member, who may not be physically present with the
participant or study personnel. Likewise, using research navigators
to help participants during the recruitment process is an effective
approach for enhancing minority participation in clinical trials [37].
However, coordinating three individuals to be at the same time and
place to provide consent can be a logistical challenge. Fortunately,
by using teleconsent with Doxy.me's three-way call capabilities,
researchers can obtain consent from all parties even if all arepresent at different locations. Indeed, three-way teleconsent can be
beneﬁcial for informed consent use cases that require three sig-
natures. Additionally, researchers have become more successful
with direct-to-participant online recruiting approaches, including
using trial registry websites (e.g., ResearchMatch.org) and social
media (e.g., Facebook) [38,39]. However, these online approaches
still face the difﬁcult task of obtaining informed consent from the
participant, hence limiting their potential. Nevertheless, by incor-
porating teleconsent into an online recruitment strategy, interested
participants can instantaneously connect with research personnel
and provide their consent through teleconsent, right at the time at
which they are most interested to participate. Adding teleconsent
to online recruiting removes several steps that result in lost op-
portunities from the traditional consent approach.3.4. Limitations of teleconsent
Although teleconsent offers many beneﬁts to researchers, a
number of its limitations need to be considered before being uti-
lized for informed consent in clinical research. First, teleconsent
requires the participant to have access to a computer with a good
internet connection. While a large portion of the population will
have direct access to these capabilities (67% with access to broad-
band at home, and 13% with access to internet through smart-
phone), not everyone will. However, the socioeconomic digital
divide isn't as large as one might presume. For example, 62% of
individuals with lower socioeconomic status have broadband or
smartphone access. Even among minorities, smartphone adoption
is often higher than among Caucasians [40]. To cater for such
population groups, teleconsent can be used in a remote clinic,
community center, public library, church, etc where the techno-
logical infrastructure available to access the internet. Second, ef-
forts are underway to improve the teleconsent compatibility on
tablets and smartphones as it is currently limited. However, based
on our experience, larger computer screens make it easier for
participants to read the document text and follow along compared
to smaller screens on mobile devices. Nevertheless, access to par-
ticipants can increase as many people primarily access the internet
using a mobile device [41]. Third, for various reasons, such as
comfort level in using electronic devices or sharing their informa-
tion over a video call, not all participants will feel comfortable
providing consent using teleconsent. However, teleconsent is a
compliment to the traditional in-person paper consent, rather than
a replacement, so its use is not meant to be absolute, but rather a
compliment to other consent strategies. In cases where it is
appropriate and the participant is comfortable, teleconsent is a
good option to obtain consent from participants remotely. Fourth,
as with any technology, organizations may require institutional
approval, training and management protocol, and IT support. These
requirements may add a layer of complexity above traditional
paper-based consent already available. Finally, in its current
version, teleconsent lacks some workﬂow components that reduce
the burden on IT support and researchers, including (1) allowing
researchers to author their consents and submitting them for
electronic approval by the IRB, and (2) automated capture of the
consent into the clinical trials system of record and capture of the
participant options via checkboxes as computable data elements
for storage and retrieval. The latter is particularly important when
working with consents that include collections of biospecimens for
future use to ensure compliance with the participants' permissions
for their use. Nevertheless, it is not beyond possibility for tele-
consent to add such features, or to add teleconsent capabilities to
eConsent tools.
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To promote adoption and utilization of teleconsent, it is
important to measure the impact on clinical trial recruitment and
consent. To that end, studies are currently underway or planned to
a) evaluate the impact of teleconsent on recruitment, and b) to
provide a comparison between teleconsent and other recruitment
approaches to measure participation rate. The goal of this manu-
script is to describe the technology in detail to set the stage for
these future publications in preparation.
4. Conclusion
Obtaining informed consent for research can be a challenging
task, which can impact the ultimate success of a study. Teleconsent
is a new technology that leverages telemedicine technology to
overcome barriers related to participant access. With teleconsent, a
researcher can interactively complete a consent document with a
participant in real time as part of a video call. By making it easier
and more convenient for a participant to provide consent remotely,
researchers are able to improve study recruitment and accrual
rates, leading to more efﬁcient and effective clinical research.
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